Annals of Hematology

, Volume 87, Issue 1, pp 43–48 | Cite as

BEAC or BEAM high-dose chemotherapy followed by autologous stem cell transplantation in non-Hodgkin’s lymphoma patients: comparative analysis of efficacy and toxicity

  • Jae-Cheol Jo
  • Byung Wook Kang
  • Geundoo Jang
  • Sun Jin Sym
  • Sung Sook Lee
  • Ja Eun Koo
  • Jong Wook Kim
  • Shin Kim
  • Jooryung Huh
  • Cheolwon Suh
Original Article

Abstract

The treatment of choice for relapsed/refractory non-Hodgkin’s lymphoma (NHL) consists of high-dose chemotherapy (HDC) followed by autologous stem cell transplantation (ASCT). Little is known, however, regarding the comparative toxicity and efficacy of various HDC regimens applied in NHL. We have retrospectively evaluated the clinical aspects of the BCNU, etoposide, cytarabine, and cyclophosphamide (BEAC) and BCNU, etoposide, cytarabine, and melphalan (BEAM) regimens for ASCT. Between April 1994 and February 2005, 97 NHL patients underwent HDC with BEAC (N = 69) or BEAM (N = 28), followed by ASCT, at the Asan Medical Center. We matched each BEAM patient with two BEAC patients having the same International Prognostic Index. Thus, 84 patients (56 BEAC and 28 BEAM) were analyzed. Median age was 40.5years, and baseline characteristics were well balanced between the two groups. The median time to neutrophil engraftment (>500/mm3) was significantly longer with BEAC than with BEAM (12 vs 11days, P = 0.001), as was the total amount of red blood cell transfusion (6.5 vs 3.7U, P = 0.037), but the median time to platelet engraftment (>20,000/mm3) and the total amount of platelet transfusion did not differ between the two groups. BEAM patients had significantly more frequent World Health Organization grade greater than or equal to 2 diarrhea than BEAC patients (46.4 vs 19.6%, P = 0.010), but the incidence of mucositis, nausea/vomiting, and bleeding and the number of episodes of febrile neutropenia and septicemia did not differ between the two groups. Median follow-up for survivors was 33months in the BEAM group and 89months in the BEAC group. Median overall survival and median event-free survival were not reached in the BEAM group and were 7.9 (95% confidence interval [CI], 1–14.8months, P = 0.003) and 3.7months (95% CI, 0.1–7.2months, P = 0.001), respectively, in the BEAC group. BEAM appeared to be superior to BEAC for survival. Regimen-related toxicities were similar, except that BEAM was associated with more frequent but acceptable diarrhea.

Keywords

Non-Hodgkin’s lymphoma Autologous stem cell transplantation BEAM BEAC Survival Toxicity 

References

  1. 1.
    Philip T, Armitage JO, Spitzer G et al (1987) High-dose therapy and autologous bone marrow transplantation after failure of conventional chemotherapy in adults with intermediate-grade or high-grade non-Hodgkin’s lymphoma. N Engl J Med 316:1493–1498PubMedCrossRefGoogle Scholar
  2. 2.
    Philip T, Guglielmi C, Hagenbeek A et al (1995) Autologous bone marrow transplantation as compared with salvage chemotherapy in relapses of chemotherapy-sensitive non-Hodgkin’s lymphoma. N Engl J Med 333:1540–1545PubMedCrossRefGoogle Scholar
  3. 3.
    Blay J, Gomez F, Sebban C et al (1998) The International Prognostic Index correlates to survival in patients with aggressive lymphoma in relapse: analysis of the PARMA trial. Blood 92:3562–3568PubMedGoogle Scholar
  4. 4.
    Milpied N, Deconinck E, Gaillard F et al (2004) Initial treatment of aggressive lymphoma with high-dose chemotherapy and autologous stem-cell support. N Engl J Med 350:1287–1295PubMedCrossRefGoogle Scholar
  5. 5.
    The International Non-Hodgkin’s Lymphoma Prognostic Factors Project (1993) A predictive model for aggressive non-Hodgkin’s lymphoma. N Engl J Med 329:987–994CrossRefGoogle Scholar
  6. 6.
    Shipp MA, Abeloff MD, Antman KH et al (1999) International consensus conference on high-dose therapy with hematopoietic stem cell transplantation in aggressive non-Hodgkin's lymphomas: report of the jury. J Clin Oncol 17:423–429PubMedGoogle Scholar
  7. 7.
    Mounier N, Gisselbrecht C (1998) Conditioning regimens before transplantation in patients with aggressive non-Hodgkin’s lymphoma. Ann Oncol 9(Suppl 1):S15–S21PubMedCrossRefGoogle Scholar
  8. 8.
    Salar A, Sierra J, Gandarillas M et al (2001) Autologous stem cell transplantation for clinically aggressive non-Hodgkin’s lymphoma: the role of preparative regimens. Bone Marrow Transplant 27:405–412PubMedCrossRefGoogle Scholar
  9. 9.
    Caballero MD, Rubio V, Rifon J et al (1997) BEAM chemotherapy followed by autologous stem cell support in lymphoma patients: analysis of efficacy, toxicity and prognostic factors. Bone Marrow Transplant 20:451–458PubMedCrossRefGoogle Scholar
  10. 10.
    Buser AS, Stern M, Bucher C et al (2007) High-dose chemotherapy using BEAM without autologous rescue followed by reduced-intensity conditioning allogeneic stem-cell transplantation for refractory or relapsing lymphomas: a comparison of delayed versus immediate transplantation. Bone Marrow Transplant 39:335–340PubMedCrossRefGoogle Scholar
  11. 11.
    Argiris A, Seropian S, Cooper DL (2000) High-dose BEAM chemotherapy with autologous peripheral blood progenitor-cell transplantation for unselected patients with primary refractory or relapsed Hodgkin's disease. Ann Oncol 11:665–672PubMedCrossRefGoogle Scholar
  12. 12.
    Buadi FK, Micallef IN, Ansell SM et al (2006) Autologous hematopoietic stem cell transplantation for older patients with relapsed non-Hodgkin’s lymphoma. Bone Marrow Transplant 37:1017–1022PubMedCrossRefGoogle Scholar
  13. 13.
    Weaver CH, Schwartzberg L, Zhen B et al (1997) High-dose chemotherapy and peripheral blood stem cell infusion in patients with non-Hodgkin’s lymphoma: results of outpatient treatment in community cancer centers. Bone Marrow Transplant 20:753–760PubMedCrossRefGoogle Scholar
  14. 14.
    Jantunen E, Itala M, Juvonen E et al (2006) Autologous stem cell transplantation in elderly (>60 years) patients with non-Hodgkin’s lymphoma: a nation-wide analysis. Bone Marrow Transplant 37:367–372PubMedCrossRefGoogle Scholar
  15. 15.
    Cheson BD, Horning SJ, Coiffier B et al (1999) Report of an international workshop to standardize response criteria for non-Hodgkin’s lymphomas. J Clin Oncol 17:1244–1253PubMedGoogle Scholar
  16. 16.
    Kaplan EL, Meier P (1958) Nonparametric estimation from incomplete observations. J Am Stat Assoc 53:457–481CrossRefGoogle Scholar
  17. 17.
    Peto R, Peto J (1972) Asymptotically efficient rank invariant test procedures. JR Stat Soc 135:185–206Google Scholar
  18. 18.
    Jantunen E, Kuittinen T, Nousiainen T (2003) BEAC or BEAM for high-dose therapy in patients with non-Hodgkin's lymphoma? A single centre analysis on toxicity and efficacy. Leuk Lymphoma 44:1151–1158PubMedCrossRefGoogle Scholar
  19. 19.
    Wang EH, Chen YA, Corringham S et al (2004) High-dose CEB vs BEAM with autologous stem cell transplant in lymphoma. Bone Marrow Transplant 34:581–587PubMedCrossRefGoogle Scholar
  20. 20.
    Mills W, Chopra R, McMillan A et al (1995) BEAM chemotherapy and autologous bone marrow transplantation for patients with relapsed or refractory non-Hodgkin’s lymphoma. J Clin Oncol 13:588–595PubMedGoogle Scholar
  21. 21.
    Samuels BL, Bitran JD (1995) High-dose intravenous melphalan: a review. J Clin Oncol 13:1786–1799PubMedGoogle Scholar
  22. 22.
    Hamlin PA, Zelenetz AD, Kewalramani T et al (2003) Age-adjusted International Prognostic Index predicts autologous stem cell transplantation outcome for patients with relapsed or primary refractory diffuse large B-cell lymphoma. Blood 102:1989–1996PubMedCrossRefGoogle Scholar
  23. 23.
    Rodriguez J, Caballero MD, Gutierrez A et al (2003) High dose chemotherapy and autologous stem cell transplantation in patients with peripheral T-cell lymphoma not achieving complete response after induction chemotherapy. The GEL-TAMO experience. Haematologica 88:1372–1377PubMedGoogle Scholar
  24. 24.
    Kim MK, Kim S, Lee SS et al (2007) High-dose chemotherapy and autologous stem cell transplantation for peripheral T-cell lymphoma: complete response at transplant predicts survival. Ann Hematol 86:435–442PubMedCrossRefGoogle Scholar

Copyright information

© Springer-Verlag 2007

Authors and Affiliations

  • Jae-Cheol Jo
    • 1
  • Byung Wook Kang
    • 1
  • Geundoo Jang
    • 1
  • Sun Jin Sym
    • 1
  • Sung Sook Lee
    • 1
  • Ja Eun Koo
    • 1
  • Jong Wook Kim
    • 1
  • Shin Kim
    • 1
  • Jooryung Huh
    • 2
  • Cheolwon Suh
    • 1
  1. 1.Department of Internal MedicineAsan Medical CenterSeoulSouth Korea
  2. 2.Department of Pathology, Asan Medical CenterUniversity of Ulsan College of MedicineSeoulSouth Korea

Personalised recommendations